Drug Development and the Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Disease Modeling and Drug Toxicity Screening

Over the years, numerous groups have employed human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating the function and dysfunction of cardiomyocytes, drug screening and toxicity, disease modeling and for the development of novel drug...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2020-10, Vol.21 (19), p.7320
Main Authors: Ovics, Paz, Regev, Danielle, Baskin, Polina, Davidor, Mor, Shemer, Yuval, Neeman, Shunit, Ben-Haim, Yael, Binah, Ofer
Format: Article
Language:English
Subjects:
Adverse Drug Reactions (ADRs)
Biocompatibility
Cardiac arrhythmia
Cardiomyocytes
Cardiotoxicity
Cardiotoxicity - diagnosis
Cardiotoxicity - drug therapy
cardiotoxiciy
Cell Differentiation - drug effects
channelopathies
Clinical trials
Coronary artery disease
Critical path
Disease
Drug development
Drug Evaluation, Preclinical - methods
Drug screening
Drug-Related Side Effects and Adverse Reactions
Drugs
Failure
Health aspects
Heart cells
Heart diseases
Heart Diseases - drug therapy
Heart Diseases - pathology
Humans
Induced Pluripotent Stem Cells - cytology
Induced Pluripotent Stem Cells - drug effects
iPSC-CMs
Marketing
Modelling
Myocytes, Cardiac - cytology
Myocytes, Cardiac - drug effects
Nonsteroidal anti-inflammatory drugs
Pharmaceutical industry
Pharmacokinetics
Pluripotency
Review
Stem cells
structural mutations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Over the years, numerous groups have employed human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) as a superb human-compatible model for investigating the function and dysfunction of cardiomyocytes, drug screening and toxicity, disease modeling and for the development of novel drugs for heart diseases. In this review, we discuss the broad use of iPSC-CMs for drug development and disease modeling, in two related themes. In the first theme-drug development, adverse drug reactions, mechanisms of cardiotoxicity and the need for efficient drug screening protocols-we discuss the critical need to screen old and new drugs, the process of drug development, marketing and Adverse Drug reactions (ADRs), drug-induced cardiotoxicity, safety screening during drug development, drug development and patient-specific effect and different mechanisms of ADRs. In the second theme-using iPSC-CMs for disease modeling and developing novel drugs for heart diseases-we discuss the rationale for using iPSC-CMs and modeling acquired and inherited heart diseases with iPSC-CMs.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms21197320